司帕沙星治疗感染性疾病的多中心临床研究

比较司帕沙星片剂和氧氟沙星片剂治疗呼吸系统,泌尿系统和消化系统感染的疗效和安全性。方法：在上海市７所医院进行多中心、随机、对照研究,司帕沙星组（试验组）１１０例,２００ｍｇ,１次／ｄ;氧氟沙星组（对照组）１１０例,２００ｍｇ,２－３次／ｄ。均口服,疗程均为７－１４ｄ。结果：试验组和对照组的治疗有效率分别为９１．８％和８２．７％,痊愈率分别为６３．３％和５６．４％,细菌清除率分别为９４．３％和８８．

Multicentre clinical study on domestic sparfloxacin in treatment of patients with infectious diseases

Objective:To investigate the efficacy and safety of sparfloxacin in treatment of patients with infections like respiratory tract infections, urinary tract infections and digestive tract infections compared with ofloxacin. Methods: In this multicentre, randomized and comparative study was completed in 7 hospitals in Shanghai, sparfloxacin was administered orally 200 mg once daily for up to 7 14 days to treat 110 patients with infections(test group), and ofloxacin was administered orally 200 mg 2 3 times daily for up to 7 14 days to treat 110 patients with infections(control group). Results: In the test group and control group, the overall efficacy were 91.8% and 82.7%,the clinical curative rates were 63.3% and 56.4%,the eradication rates were 94.3% and 88.7%, and the side effect rates were 2.7% and 1.8%, respectively( P >0.05). There were no statistical difference between the 2 groups when the clinical efficacy and the clinical curative rates were compared in treatment of respiratory tract infections, urinary tract infections and digestive tract infections. Conclusion: The efficacy and safety of sparfloxacin are similar to that of ofloxacin in treatment of infectious diseases, and sparfloxacin should be recomanded in clinical because of its facility of administration.